Abstract
The search for non-invasive tools for the diagnosis and management of cancer has long been a major goal of cancer research. Cost-effective technologies for blood-based, sensitive and specific detection of nucleic acid biomarkers could potentially transform the way cancer is diagnosed and treated. Circulating microRNAs in blood have recently emerged as clinically useful and minimally invasive predictive, diagnostic and prognostic biomarkers for prostate cancer. However, they are very challenging to detect accurately due to their low concentration and high sequence homology. Herein we highlight the main limitations of the current gold-standard technologies for microRNA detection (including complexity and cost) and discuss recent technological advances toward new blood tests suitable for widespread public screening.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
